The Company has been issued 18 U.S. patents, and over 95 patents globally, on cannabinoid processing including extraction, distillation, and acetylation. Nextleaf initially files its patents in the United States to create a priority date and allow for future filings in other selected jurisdictions. This is common in the field of intellectual property (“IP”) protection. The Company owns issued patents in the United States, Canada, Mexico, Israel, Germany, Australia, Colombia, South Africa, the U.K., and across Europe. Nextleaf follows a global IP strategy of protecting the means to producing standardized cannabinoid-based products at scale within a regulated market.
Medical cannabis is currently legal in Jamaica and possession of small amounts of marijuana was decriminalized in 2015, with residents permitted to grow up to five plants for personal use only.
“This patent reinforces our vision of developing intellectual property that improves cannabis oil economics globally,” said Paul Pedersen, CEO of Nextleaf Solutions. “We believe there will be a regulated commercial market for cannabinoid-based products in Jamaica during the 20-year life of this patent.”
Nextleaf Issues Warrants
The Company has issued 500,000 warrants to purchase common shares of the Company to the holder of the convertible note issued on March 31, 2021 (the “Note”). The warrants were issued as consideration for revision of terms of the Note and are exercisable at a price of $0.138 per share for a period of 36 months from the date of issuance.